Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen ...
Genomenon's Curation and Global Distribution of Variant Data Reduces Barriers to Genetic Diagnosis ANN ARBOR, Mich., March 10, 2026 /PRNewswire/ -- Genomenon today announced a strategic sponsorship ...
Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by ...
European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, ...
This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for ...
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...
Italy’s Chiesi Group and Israel’s Protalix BioTherapeutics have announced that the European Commission (EC) has approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio (pegunigalsidase ...
Qure (NasdaqGS:QURE) released updated clinical data for its gene therapy candidate AMT-191 in Fabry disease and paused new dosing to review safety findings. The company is also facing a newly filed ...
In recent weeks, uniQure has faced heightened scrutiny after FDA Commissioner Marty Makary raised concerns about the safety and perceived lack of benefit of its AMT-130 Huntington’s disease gene ...
Detailed price information for Acumen Pharmaceuticals Inc (ABOS-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results